EVGN — Evogene Ltd.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-11 | RECANATI LEON Director | Open-market purchase | 460.0K | 0.64 | 292.1K |
| 2026-08-04 | RECANATI LEON Director | Open-market purchase | 800.0K | 0.50 | 400.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | 351.6K | 456.6K |
| JANE STREET GROUP, LLC | 14.2K | 18.5K |
| XTX Topco Ltd | 9.8K | 12.7K |
| TWO SIGMA SECURITIES, LLC | 9.6K | 12.5K |
| Daytona Street Capital LLC | 7.7K | 9.6K |
| BNP PARIBAS FINANCIAL MARKETS | 7.0K | 9.1K |
| UBS Group AG | 4.9K | 6.4K |
| MORGAN STANLEY | 3.0K | 3.9K |
| Steward Partners Investment Advisory, LLC | 389 | 505 |
| Federation des caisses Desjardins du Quebec | 385 | 500 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 6-K | 2026-08-18 | 2026-08-18 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-08-13 | — | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-08-13 | — | on EDGAR ↗ |
| 4 | 2026-08-13 | 2026-08-11 | on EDGAR ↗ |
| SCHEDULE 13D | 2026-08-11 | — | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-08-07 | — | on EDGAR ↗ |
| 4 | 2026-08-05 | 2026-08-04 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Evogene Reports Second Quarter and First Half 2026 Financial Results · 2026-08-18
- Evogene GAAP EPS of -$0.13 beats by $0.14, revenue of $0.35M beats by $0.02M · 2026-08-18
- Evogene Ltd. (EVGN) filed form 6-K · 2026-08-18 · SEC EDGAR
- Evogene Q2 2026 Earnings Preview · 2026-08-17
- Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation · 2026-08-14
Ask the AI about EVGN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →